×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
NYSE:EW

Edwards Lifesciences (EW) Stock Forecast, Price & News

$101.12
+2.55 (+2.59%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$99.21
$101.29
50-Day Range
$93.27
$128.27
52-Week Range
$91.52
$131.73
Volume
2.45 million shs
Average Volume
2.79 million shs
Market Capitalization
$62.87 billion
P/E Ratio
41.44
Dividend Yield
N/A
Beta
1.16
30 days | 90 days | 365 days | Advanced Chart
Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

Edwards Lifesciences logo

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
28176E10
Employees
15,700
Year Founded
1958

Sales & Book Value

Annual Sales
$5.23 billion
Cash Flow
$2.64 per share
Book Value
$9.40 per share

Profitability

Net Income
$1.50 billion
Pretax Margin
32.65%

Debt

Price-To-Earnings

Miscellaneous

Free Float
613,731,000
Market Cap
$62.87 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/26/2022
Today
5/28/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.62 out of 5 stars

Medical Sector

80th out of 1,424 stocks

Surgical Appliances & Supplies Industry

5th out of 30 stocks

Analyst Opinion: 4.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -













Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

Is Edwards Lifesciences a buy right now?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 3 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Edwards Lifesciences stock.
View analyst ratings for Edwards Lifesciences
or view top-rated stocks.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 4,860,000 shares, a decline of 15.2% from the April 15th total of 5,730,000 shares. Based on an average daily trading volume, of 2,740,000 shares, the short-interest ratio is presently 1.8 days. Currently, 0.8% of the shares of the company are sold short.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Edwards Lifesciences
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) announced its quarterly earnings results on Tuesday, April, 26th. The medical research company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.02. The medical research company had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.31 billion. Edwards Lifesciences had a net margin of 28.72% and a trailing twelve-month return on equity of 25.80%. The firm's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.54 earnings per share.
View Edwards Lifesciences' earnings history
.

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences's stock split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY22 earnings guidance on Tuesday, April, 26th. The company provided EPS guidance of $2.50-2.65 for the period, compared to the consensus EPS estimate of $2.56. The company issued revenue guidance of $5.5-6.0 billion, compared to the consensus revenue estimate of $5.76 billion.

What price target have analysts set for EW?

22 Wall Street analysts have issued 1-year price targets for Edwards Lifesciences' shares. Their forecasts range from $105.00 to $145.00. On average, they expect Edwards Lifesciences' share price to reach $128.71 in the next year. This suggests a possible upside of 27.3% from the stock's current price.
View analysts' price targets for Edwards Lifesciences
or view top-rated stocks among Wall Street analysts.

Who are Edwards Lifesciences' key executives?
Edwards Lifesciences' management team includes the following people:
What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences CEO Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among Edwards Lifesciences' employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.17%), Vanguard Group Inc. (8.00%), State Street Corp (4.33%), Capital International Investors (3.56%), Bank of New York Mellon Corp (3.51%) and Brown Advisory Inc. (2.67%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends for Edwards Lifesciences
.

Which institutional investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Capital Research Global Investors, Wellington Management Group LLP, Invesco Ltd., Sumitomo Mitsui Trust Holdings Inc., Neuberger Berman Group LLC, Canada Pension Plan Investment Board, and Aviva PLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Bernard J Zovighian, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, and Michael A Mussallem.
View insider buying and selling activity for Edwards Lifesciences
or view top insider-selling stocks.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., CI Investments Inc., Stonehage Fleming Financial Services Holdings Ltd, Lord Abbett & CO. LLC, Swiss National Bank, Bridgewater Associates LP, Fisher Asset Management LLC, and Woodline Partners LP.
View insider buying and selling activity for Edwards Lifesciences
or or view top insider-buying stocks.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $101.12.

How much money does Edwards Lifesciences make?

Edwards Lifesciences has a market capitalization of $62.87 billion and generates $5.23 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.439990 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

Edwards Lifesciences employs 15,700 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?

The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.

When was Edwards Lifesciences founded?

Edwards Lifesciences was founded in 1958.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is www.edwards.com.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at (949) 250-2500, via email at [email protected], or via fax at 949-250-2525.

This page was last updated on 5/29/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.